Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II results presented for TAK-954 in patients with enteral feeding intolerance

June 7, 2018

Athersys expands its collaboration with Healios

June 7, 2018

EMA grants PRIME designation for dilanubicel

June 7, 2018

FDA grants orphan drug designation to TransCon PTH

June 7, 2018

4D pharma and MSD collaborate to study Keytruda and MRx-0518 combination in solid tumors

June 7, 2018

Positive results presented from ongoing phase I trial of PTI-801 in patients with CF

June 7, 2018

First healthy volunteers enrolled in phase I study of BTRX-335140

June 7, 2018

ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients

June 7, 2018

Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL

June 7, 2018

Merck & Co. synthesizes new FXIIa inhibitors

June 7, 2018

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...